Trending NewsTrending NewsNASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis $649.76 +19.46 (+3.09%) Closing price 04:00 PM EasternExtended Trading$643.47 -6.29 (-0.97%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Regeneron Pharmaceuticals Stock (NASDAQ:REGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get REGN alerts:Sign Up Key Stats Today's Range$633.60▼$651.0050-Day Range$629.68▼$781.6052-Week Range$476.49▼$821.11Volume1.17 million shsAverage Volume787,683 shsMarket Capitalization$68.69 billionP/E Ratio15.83Dividend Yield0.58%Price Target$792.65Consensus RatingModerate Buy Company Overview Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas. Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies. The company operates an integrated model that spans early discovery through late-stage development and commercial production, enabling it to move candidates from laboratory to market using internal capabilities as well as strategic collaborations. Key marketed products and development programs address ophthalmology, immunology, oncology and infectious disease. Regeneron’s marketed medicines include EYLEA (aflibercept) for retinal disorders and Dupixent (dupilumab), developed and co-commercialized in partnership with Sanofi, for certain inflammatory conditions. The company has also developed antibody-based therapies for oncology and infectious disease, including combination antibody treatments for COVID‑19 during the pandemic response. Regeneron serves patients in the United States and internationally through its own commercial operations and partner arrangements. Leadership includes founder and chief executive Leonard S. Schleifer and co‑founder and chief scientific officer George D. Yancopoulos, who have guided the company’s scientific strategy and commercial expansion. Regeneron continues to invest in platform technologies and a diversified pipeline aimed at advancing novel biologic therapies. AI Generated. May Contain Errors. Read More Regeneron Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreREGN MarketRank™: Regeneron Pharmaceuticals scored higher than 89% of companies evaluated by MarketBeat, and ranked 48th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 2 strong buy ratings, 15 buy ratings, 10 hold ratings, and no sell ratings.Upside PotentialRegeneron Pharmaceuticals has a consensus price target of $792.65, representing about 22.0% upside from its current price of $649.76.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth11.89% Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 11.89% in the coming year, from $37.10 to $41.51 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 15.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 15.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.74.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 1.40. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Regeneron Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.33% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 4.06.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 15.08%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRegeneron Pharmaceuticals has a dividend yield of 0.60%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Regeneron Pharmaceuticals is 9.16%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Regeneron Pharmaceuticals will have a dividend payout ratio of 9.06% next year. This indicates that Regeneron Pharmaceuticals will be able to sustain or increase its dividend.Read more about Regeneron Pharmaceuticals' dividend. News and Social Media2.7 / 5News Sentiment0.33 News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 72 news articles for Regeneron Pharmaceuticals this week, compared to 13 articles on an average week.Search InterestOnly 14 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat Follows14 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $70,524.00 in company stock.Percentage Held by Insiders6.97% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REGN Stock News HeadlinesRegeneron’s REGN7544 Trial Reaches Key Milestone in Sepsis-Induced HypotensionMay 20 at 12:30 PM | tipranks.comRegeneron sinks 10% on failed phase 3 melanoma trial. What comes next for REGN stock?May 19 at 11:07 PM | msn.comA 17-year investing experiment investigated in DublinPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 20 at 1:00 AM | Porter & Company (Ad)Why Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its GoalMay 19 at 11:07 PM | finance.yahoo.comRegeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2BMay 19 at 6:06 PM | finance.yahoo.comA Look At Regeneron Pharmaceuticals (REGN) Valuation After Melanoma Trial Setback And Share Price PullbackMay 19 at 1:05 PM | finance.yahoo.comREGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law ViolationsMay 19 at 9:00 AM | prnewswire.comArthur Ryan Sells 100 Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) StockMay 5, 2026 | insidertrades.comSee More Headlines REGN Stock Analysis - Frequently Asked Questions How have REGN shares performed this year? Regeneron Pharmaceuticals' stock was trading at $771.87 at the beginning of the year. Since then, REGN shares have decreased by 15.8% and is now trading at $649.76. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings data on Wednesday, April, 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. The company's revenue was up 19.0% on a year-over-year basis. Read the conference call transcript. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and more. Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' top institutional investors include Bank of America Corp DE (1.13%), Amundi (0.96%), Bank of New York Mellon Corp (0.72%) and Dimensional Fund Advisors LP (0.49%). Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Jason Pitofsky, Christine A Poon, Huda Y Zoghbi, Bonnie L Bassler and Michael S Brown. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Record date for 3/5 Dividend2/20/2026Ex-Dividend for 3/5 Dividend2/20/2026Dividend Payable3/05/2026Last Earnings4/29/2026Today5/20/2026Record date for 6/4 Dividend5/20/2026Ex-Dividend for 6/4 Dividend5/20/2026Dividend Payable6/04/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/08/2026AGM 20266/12/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 2 days ago, REGN's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees15,410Year Founded1988Price Target and Rating Average Price Target for Regeneron Pharmaceuticals$792.65 High Price Target$995.00 Low Price Target$255.00 Potential Upside/Downside+22.0%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage27 Analysts Profitability EPS (Trailing Twelve Months)$41.04 Trailing P/E Ratio15.83 Forward P/E Ratio17.51 P/E Growth1.4Net Income$4.50 billion Net Margins29.65% Pretax Margin34.56% Return on Equity13.16% Return on Assets10.17% Debt Debt-to-Equity Ratio0.06 Current Ratio3.57 Quick Ratio2.96 Sales & Book Value Annual Sales$14.34 billion Price / Sales4.79 Cash Flow$43.32 per share Price / Cash Flow15.00 Book Value$297.23 per share Price / Book2.19Miscellaneous Outstanding Shares105,720,000Free Float98,351,000Market Cap$68.69 billion OptionableOptionable Beta0.30 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:REGN) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredFed story no one is tellingJ.P. Morgan's Private Bank quietly advised 333 billionaire families to move 60% of their portfolios into alter...TradeSmith | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredThe sell discipline that changed my mind after 30 yearsPorter Stansberry spent 30 years ignoring outside investment systems - until he met Emmet Savage in Dublin. Sa...Porter & Company | SponsoredMemorial Day Event: Save 79% on Weiss Ratings Plus!Elon Musk calls it 'mind-blowing.' Fox News calls the scramble for it 'the new arms race.' Chris Graebe, Chief...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
